Clinical practice guidelines generally recommend people try "lifestyle modification", including a cholesterol-lowering diet and physical exercise, before statin use. Statins or other pharmacologic agents may be recommended for those who do not meet their lipid-lowering goals through diet and lifestyle changes. Statins appear to work equally well in males and females.
Most evidence suggests that statins are effective in preventing heart disease in those with high cholesterol, but no history of heart disease. A 2013 Cochrane review found a decrease in risk of death and other poor outcomes without any evidence of harm. For every 138 people treated for 5 years one fewer dies and for every 49 treated one fewer has an episode of heart disease. A 2011 review reached similar conclusions. And a 2012 review found benefits in both women and men. A 2010 review concluded that treating people with no history of cardiovascular disease reduces cardiovascular events in men but not women, and provides no mortality benefit in either sex. Two other meta-analyses published that year, one of which used data obtained exclusively from women, found no mortality benefit in primary prevention.
The National Institute for Health and Clinical Excellence (NICE) recommends statin treatment for adults with an estimated 10 year risk of developing cardiovascular disease that is greater than 10%. Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL or those with diabetes, age 40–75 with LDL-C 70–190 mg/dl; or in those with a 10-year risk of developing heart attack or stroke of 7.5% or more. In this latter group, statin assignment was not automatic, but was recommended to occur only after a clinician-patient risk discussion with shared decision making where other risk factors and lifestyle are addressed, the potential for benefit from a statin is weighed against the potential for adverse effects or drug interactions and informed patient preference is elicited. Moreover, if a risk decision was uncertain, factors such as family history, coronary calcium score, ankle-brachial index, and an inflammation test (hs-CRP ≥ 2.0 mg/L) were suggested to inform the risk decision. Additional factors that could be used were an LDL-C ≥ 160 or a very high lifetime risk. However, critics such as Steven E. Nissen say that the AHA/ACC guidelines were not properly validated, overestimate the risk by at least 50%, and recommend statins for patients who will not benefit, based on populations whose observed risk is lower than predicted by the guidelines. The European Society of Cardiology and the European Atherosclerosis Society recommend the use of statins for primary prevention, depending on baseline estimated cardiovascular score and LDL thresholds.
Statins are effective in decreasing mortality in people with pre-existing cardiovascular disease. They are also advocated for use in people at high risk of developing coronary heart disease. On average, statins can lower LDL cholesterol by 1.8 mmol/l (70 mg/dl), which translates into an estimated 60% decrease in the number of cardiac events (heart attack, sudden cardiac death) and a 17% reduced risk of stroke after long-term treatment. A greater benefit is observed with high-intensity statin therapy. They have less effect than the fibrates or niacin in reducing triglycerides and raising HDL-cholesterol ("good cholesterol").
Statins have been studied for improving operative outcomes in cardiac and vascular surgery. Mortality and adverse cardiovascular events were reduced in statin groups.
While no direct comparison exists, all statins appear effective regardless of potency or degree of cholesterol reduction. There do appear to be some differences between them, with simvastatin and pravastatin appearing superior in terms of side-effects.
A comparison of simvastatin, pravastatin, and atorvastatin, based on their effectiveness against placebos, found, at commonly prescribed doses, no differences among the statins in reducing cardiovascular morbidity and mortality, and lipids.
In children statins are effective at reducing cholesterol levels in those with familial hypercholesterolemia. Their long term safety is, however, unclear. Some recommend that if lifestyle changes are not enough statins should be started at 8 years old.
Statins may be less effective in reducing LDL cholesterol in people with familial hypercholesterolemia, especially those with homozygous deficiencies. These people have defects usually in either the LDL receptor or apolipoprotein B genes, both of which are responsible for LDL clearance from the blood. Statins remain a first-line treatment in familial hypercholesterolemia, although other cholesterol-reducing measures may be required. In people with homozygous deficiencies, statins may still prove helpful, albeit at high doses and in combination with other cholesterol-reducing medications.
The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin.
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. This could be because, as statins inhibit the enzyme (HMG-CoA reductase) that makes cholesterol, statins also inhibit the other processes of this enzyme, such as CoQ10 production, and CoQ10 production is important for muscle cells and in blood sugar regulation.
Other possible adverse effects include neuropathy, pancreatic and liver dysfunction, and sexual dysfunction. The rate at which such events occur has been widely debated, in part because the risk/benefit ratio of statins in low-risk populations is highly dependent on the rate of adverse events. A Cochrane meta-analysis of statin clinical trials in primary prevention found no evidence of excess adverse events among those treated with statins compared to placebo. Another meta-analysis found a 39% increase in adverse events in statin treated people relative to those receiving placebo, but no increase in serious adverse events. The author of one study argued that adverse events are more common in clinical practice than in randomized clinical trials. A systematic review concluded that while clinical trial meta-analyses underestimate the rate of muscle pain associated with statin use, the rates of rhabdomyolysis are still "reassuringly low" and similar to those seen in clinical trials (about 1–2 per 10,000 person years). A systematic review co-authored by Ben Goldacre concluded that only a small fraction of side effects reported by people on statins are actually attributable to the statin.
There are reports of cognitive decline with statins. In 2012, in recognition of an increase in reports and increasing concerns over the relationship between statins and memory loss (including reports of transient global amnesia), forgetfulness and confusion, the Food and Drug Administration (FDA) added to its required labeling on statin medications a warning about possible cognitive impacts. The effects are described as rare, non-serious, and reversible upon cessation of treatment.
Multiple systematic reviews and meta-analyses have concluded that the available evidence does not support an association between statin use and cognitive decline.
In observational studies 10–15% of people who take statins experience muscle problems; in most cases these consist of muscle pain. These rates, which are much higher than those seen in randomized clinical trials have been the topic of extensive debate and discussion.
Rare reactions include myopathies such as myositis (inflammation of the muscles) or even rhabdomyolysis (destruction of muscle cells), which can in turn result in life-threatening kidney injury. The risk of statin-induced rhabdomyolysis increases with older age, use of interacting medications such as fibrates, and hypothyroidism.Coenzyme Q10 (ubiquinone) levels are decreased in statin use; CoQ10 supplements are sometimes used to treat statin-associated myopathy, though evidence of their efficacy is lacking as of 2007[update]. The gene SLCO1B1 (Solute carrier organic anion transporter family member 1B1) codes for an organic anion-transporting polypeptide that is involved in the regulation of the absorption of statins. A common variation in this gene was found in 2008 to significantly increase the risk of myopathy.
Records exist of over 250,000 people treated from 1998 to 2001 with the statin drugs atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The incidence of rhabdomyolyis was 0.44 per 10,000 patients treated with statins other than cerivastatin. However, the risk was over 10-fold greater if cerivastatin was used, or if the standard statins (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) were combined with a fibrate (fenofibrate or gemfibrozil) treatment. Cerivastatin was withdrawn by its manufacturer in 2001.
Some researchers have suggested hydrophilic statins, such as fluvastatin, rosuvastatin, and pravastatin, are less toxic than lipophilic statins, such as atorvastatin, lovastatin, and simvastatin, but other studies have not found a connection.Lovastatin induces the expression of gene atrogin-1, which is believed to be responsible in promoting muscle fiber damage. Tendon rupture does not appear to occur.
The relationship between statin use and risk of developing diabetes remains unclear and the results of systematic reviews and meta-analyses are mixed. Higher doses have a greater effect, but the decrease in cardiovascular disease outweighs the risk of developing diabetes. Use in postmenopausal women is associated with an increased risk for diabetes. The exact mechanism responsible for the possible increased risk of diabetes mellitus associated with statin use is unclear. Statins are thought to decrease cells' uptake of glucose from the bloodstream in response to the hormoneinsulin. One way this is thought to occur is by interfering with cholesterol synthesis which is necessary for the production of certain proteins responsible for glucose uptake into cells such as GLUT1.
Several meta-analyses have found no increased risk of cancer, and some meta-analyses have found a reduced risk.
Combining any statin with a fibrate or niacin (other categories of lipid-lowering drugs) increases the risks for rhabdomyolysis to almost 6.0 per 10,000 person-years. Monitoring liver enzymes and creatine kinase is especially prudent in those on high-dose statins or in those on statin/fibrate combinations, and mandatory in the case of muscle cramps or of deterioration in kidney function.
Consumption of grapefruit or grapefruit juiceinhibits the metabolism of certain statins. Bitter oranges may have a similar effect. Furanocoumarins in grapefruit juice (i.e. bergamottin and dihydroxybergamottin) inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of most statins (however, it is a major inhibitor of only lovastatin, simvastatin, and to a lesser degree, atorvastatin) and some other medications (flavonoids (i.e. naringin) were thought to be responsible). This increases the levels of the statin, increasing the risk of dose-related adverse effects (including myopathy/rhabdomyolysis). The absolute prohibition of grapefruit juice consumption for users of some statins is controversial.
The FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy). The most serious form of myopathy, rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.
Mechanism of action
Atorvastatin bound to HMG-CoA reductase: PDB entry 1hwk
The HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate limiting enzyme HMG-CoA reductase.
By inhibiting HMG-CoA reductase, statins block the pathway for synthesizing cholesterol in the liver. This is significant because most circulating cholesterol comes from internal manufacture rather than the diet. When the liver can no longer produce cholesterol, levels of cholesterol in the blood will fall. Cholesterol synthesis appears to occur mostly at night, so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, but have shown no difference in the long-acting atorvastatin.
Increasing LDL uptake
In rabbits, liver cells sense the reduced levels of liver cholesterol and seek to compensate by synthesizing LDL receptors to draw cholesterol out of the circulation. This is accomplished via proteases that cleave membrane-bound sterol regulatory element binding proteins, which then migrate to the nucleus and bind to the sterol response elements. The sterol response elements then facilitate increased transcription of various other proteins, most notably, LDL receptor. The LDL receptor is transported to the liver cell membrane and binds to passing LDL and VLDL particles (colloquially, "bad cholesterol"), mediating their uptake into the liver, where the cholesterol is reprocessed into bile salts and other byproducts. This results in a net effect of less LDL circulating in blood.
Decreasing of specific protein prenylation
Statins, by inhibiting the HMG CoA reductase pathway, simultaneously inhibit the production of both cholesterol and specific prenylated proteins (see diagram).This inhibitory effect on protein prenylation may be involved, at least partially, in the improvement of endothelial function, modulation of immune function, and other pleiotropic cardiovascular benefits of statins, as well as in the fact that a number of other drugs that lower LDL have not shown the same cardiovascular risk benefits in studies as statins, and may also account for certain of the benefits seen in cancer reduction with statins. In addition, the inhibitory effect on protein prenylation may also be involved in a number of unwanted side effects associated with statins, including muscle pain (myopathy) and elevated blood sugar (diabetes).
LDL-lowering potency varies between agents. Cerivastatin is the most potent, (withdrawn from the market in August, 2001 due to risk of serious rhabdomyolysis) followed by (in order of decreasing potency), rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin, and fluvastatin. The relative potency of pitavastatin has not yet been fully established.
Some types of statins are naturally occurring, and can be found in such foods as oyster mushrooms and red yeast rice. Randomized controlled trials have found these foodstuffs to reduce circulating cholesterol, but the quality of the trials has been judged to be low.
Due to patent expiration, most of the block-buster branded statins have been generic since 2012, including atorvastatin, the largest-selling branded drug.
Statin equivalent dosages
% LDL reduction (approx.)
* 80-mg dose no longer recommended due to increased risk of rhabdomyolysis
In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, began the search for a cholesterol-lowering drug. Research had already shown cholesterol is mostly manufactured by the body in the liver, using the enzyme HMG-CoA reductase. Endo and his team reasoned that certain microorganisms may produce inhibitors of the enzyme to defend themselves against other organisms, as mevalonate is a precursor of many substances required by organisms for the maintenance of their cell walls (ergosterol)[dubious – discuss] or cytoskeleton (isoprenoids). The first agent they identified was mevastatin (ML-236B), a molecule produced by the fungus Penicillium citrinum.
A British group isolated the same compound from Penicillium brevicompactum, named it compactin, and published their report in 1976. The British group mentions antifungal properties, with no mention of HMG-CoA reductase inhibition.
Mevastatin was never marketed, because of its adverse effects of tumors, muscle deterioration, and sometimes death in laboratory dogs. P. Roy Vagelos, chief scientist and later CEO of Merck & Co, was interested, and made several trips to Japan starting in 1975. By 1978, Merck had isolated lovastatin (mevinolin, MK803) from the fungus Aspergillus terreus, first marketed in 1987 as Mevacor.
A link between cholesterol and cardiovascular disease, known as the lipid hypothesis, had already been suggested. Cholesterol is the main constituent of atheroma, the fatty lumps in the wall of arteries that occur in atherosclerosis and, when ruptured, cause the vast majority of heart attacks. Treatment consisted mainly of dietary measures, such as a low-fat diet, and poorly tolerated medicines, such as clofibrate, cholestyramine, and nicotinic acid. Cholesterol researcher Daniel Steinberg writes that while the Coronary Primary Prevention Trial of 1984 demonstrated cholesterol lowering could significantly reduce the risk of heart attacks and angina, physicians, including cardiologists, remained largely unconvinced.
Society and culture
To market statins effectively, Merck had to convince the public of the dangers of high cholesterol, and doctors that statins were safe and would extend lives. As a result of public campaigns, people in the United States became familiar with their cholesterol numbers and the difference between "good" and "bad" cholesterol, and rival pharmaceutical companies began producing their own statins, such as pravastatin (Pravachol), manufactured by Sankyo and Bristol-Myers Squibb. In April 1994, the results of a Merck-sponsored study, the Scandinavian Simvastatin Survival Study, were announced. Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. In 1995, Zocor and Mevacor both made Merck over US$1billion. Endo was awarded the 2006 Japan Prize, and the Lasker-DeBakey Clinical Medical Research Award in 2008. For his "pioneering research into a new class of molecules" for "lowering cholesterol," Endo was inducted into the National Inventors Hall of Fame in Alexandria, Virginia in 2012. Michael C. Brown and Joseph Goldstein, who won the Nobel Prize for related work on cholesterol, said of Endo: "The millions of people whose lives will be extended through statin therapy owe it all to Akira Endo."
Controversy over the effectiveness of statins in the medical literature was amplified in popular media in the early 2010s, leading an estimated 200,000 people in the UK to stop using statins over a six-month period to mid 2016, according to the authors of a study funded by the British Heart Foundation. They estimated that there could be up to 2,000 extra heart attacks or strokes over the following 10 years as a consequence. An unintended effect of the academic statin controversy has been the spread of scientifically questionable alternative therapies. Cardiologist Steven Nissen at Cleveland Clinic commented "We are losing the battle for the hearts and minds of our patients to Web sites..." promoting unproven medical therapies. Harriet Hall sees a spectrum of "statin denialism" ranging from pseudoscientific claims to the understatement of benefits and overstatement of side effects, all of which is contrary to the scientific evidence.
^Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (December 2007). "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths". Lancet. 370 (9602): 1829–39. doi:10.1016/S0140-6736(07)61778-4. PMID18061058.
^Sweetman, Sean C., ed. (2009). "Cardiovascular drugs". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1155–434. ISBN978-0-85369-840-1.
^National Cholesterol Education Program (2001). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute. p. 40. NIH Publication No. 01-3670.
^Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A (April 2015). "Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials". Lancet. 385 (9976): 1397–405. doi:10.1016/s0140-6736(14)61368-4. hdl:2123/14127. PMID25579834.
^ abcBibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FA, Gillman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre ML, Mangione CM, Phillips WR, Owens DK, Phipps MG, Pignone MP (November 2016). "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement". JAMA. 316 (19): 1997–2007. doi:10.1001/jama.2016.15450. PMID27838723.
^Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB (February 2012). "Meta-analysis of statin effects in women versus men". Journal of the American College of Cardiology. 59 (6): 572–82. doi:10.1016/j.jacc.2011.09.067. PMID22300691.
^Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M (January 2010). "Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis". International Journal of Cardiology. 138 (1): 25–31. doi:10.1016/j.ijcard.2008.08.001. PMID18793814.
^Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N (June 2010). "Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants". Archives of Internal Medicine. 170 (12): 1024–31. doi:10.1001/archinternmed.2010.182. PMID20585067.
^Bukkapatnam RN, Gabler NB, Lewis WR (2010). "Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis". Preventive Cardiology. 13 (2): 84–90. doi:10.1111/j.1751-7141.2009.00059.x. PMID20377811.
^Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. (June 2014). "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S1–45. doi:10.1161/01.cir.0000437738.63853.7a. PMID24222016.
^de Waal BA, Buise MP, van Zundert AA (January 2015). "Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review". British Journal of Anaesthesia. 114 (1): 44–52. doi:10.1093/bja/aeu295. PMID25186819.
^Antoniou GA, Hajibandeh S, Hajibandeh S, Vallabhaneni SR, Brennan JA, Torella F (February 2015). "Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery". Journal of Vascular Surgery. 61 (2): 519–532.e1. doi:10.1016/j.jvs.2014.10.021. PMID25498191.
^Zhou Z, Rahme E, Pilote L (February 2006). "Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention". American Heart Journal. 151 (2): 273–81. doi:10.1016/j.ahj.2005.04.003. PMID16442888.
^ abVuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E (July 2014). "Statins for children with familial hypercholesterolemia". The Cochrane Database of Systematic Reviews (7): CD006401. doi:10.1002/14651858.CD006401.pub3. PMID25054950.
^Lamaida N, Capuano E, Pinto L, Capuano E, Capuano R, Capuano V (September 2013). "The safety of statins in children". Acta Paediatrica. 102 (9): 857–62. doi:10.1111/apa.12280. PMID23631461.
^ abRepas TB, Tanner JR (February 2014). "Preventing early cardiovascular death in patients with familial hypercholesterolemia". The Journal of the American Osteopathic Association. 114 (2): 99–108. doi:10.7556/jaoa.2014.023. PMID24481802.
^Ramasamy I (February 2016). "Update on the molecular biology of dyslipidemias". Clinica Chimica Acta; International Journal of Clinical Chemistry. 454: 143–85. doi:10.1016/j.cca.2015.10.033. PMID26546829.
^Liu YH, Liu Y, Duan CY, Tan N, Chen JY, Zhou YL, Li LW, He PC (March 2015). "Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (2): 181–92. doi:10.1177/1074248414549462. PMID25193735.
^table adapted from the following source, but check individual references for technical explanations
^ abMancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J (2011). "Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference". The Canadian Journal of Cardiology. 27 (5): 635–62. doi:10.1016/j.cjca.2011.05.007. PMID21963058.
^Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP (April 2014). "What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice". European Journal of Preventive Cardiology. 21 (4): 464–74. doi:10.1177/2047487314525531. PMID24623264.
^Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS (November 2013). "Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects". Mayo Clinic Proceedings. 88 (11): 1213–21. doi:10.1016/j.mayocp.2013.07.013. PMID24095248.
^Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J (December 2013). "Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update". The Canadian Journal of Cardiology. 29 (12): 1553–68. doi:10.1016/j.cjca.2013.09.023. PMID24267801.
^Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM (November 2013). "Statins and cognitive function: a systematic review". Annals of Internal Medicine. 159 (10): 688–97. doi:10.7326/0003-4819-159-10-201311190-00007. PMID24247674.
^Potgieter M, Pretorius E, Pepper MS (March 2013). "Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation". Nutrition Reviews. 71 (3): 180–8. doi:10.1111/nure.12011. PMID23452285.
^Marcoff L, Thompson PD (June 2007). "The role of coenzyme Q10 in statin-associated myopathy: a systematic review". Journal of the American College of Cardiology. 49 (23): 2231–7. doi:10.1016/j.jacc.2007.02.049. PMID17560286.
^Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (August 2008). "SLCO1B1 variants and statin-induced myopathy--a genomewide study". The New England Journal of Medicine. 359 (8): 789–99. doi:10.1056/NEJMoa0801936. PMID18650507.
^ abGraham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (December 2004). "Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs". JAMA. 292 (21): 2585–90. doi:10.1001/jama.292.21.2585. PMID15572716.
^Backman JT, Filppula AM, Niemi M, Neuvonen PJ (January 2016). "Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions". Pharmacological Reviews (Review). 68 (1): 168–241. doi:10.1124/pr.115.011411. PMID26721703.
^Teichtahl AJ, Brady SR, Urquhart DM, Wluka AE, Wang Y, Shaw JE, Cicuttini FM (February 2016). "Statins and tendinopathy: a systematic review". The Medical Journal of Australia. 204 (3): 115–21.e1. doi:10.5694/mja15.00806. PMID26866552.
^Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID20167359.
^Chou R, Dana T, Blazina I, Daeges M, Jeanne TL (November 2016). "Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA (Review). 316 (19): 2008–2024. doi:10.1001/jama.2015.15629. PMID27838722.
^Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK (June 2011). "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis". JAMA. 305 (24): 2556–64. doi:10.1001/jama.2011.860. PMID21693744.
^Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y (January 2012). "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative". Archives of Internal Medicine. 172 (2): 144–52. doi:10.1001/archinternmed.2011.625. PMID22231607.
^Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (September 2012). "The controversies of statin therapy: weighing the evidence". Journal of the American College of Cardiology. 60 (10): 875–81. doi:10.1016/j.jacc.2012.07.007. PMID22902202.
^Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (July 2007). "Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials". Journal of the American College of Cardiology. 50 (5): 409–18. doi:10.1016/j.jacc.2007.02.073. PMID17662392.
^Alsheikh-Ali AA, Karas RH (March 2009). "The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials". Current Atherosclerosis Reports. 11 (2): 100–4. doi:10.1007/s11883-009-0016-8. PMID19228482.
^Liu Y, Tang W, Wang J, Xie L, Li T, He Y, Deng Y, Peng Q, Li S, Qin X (February 2014). "Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies". Cancer Causes & Control. 25 (2): 237–49. doi:10.1007/s10552-013-0326-6. PMID24265089.
^Wu XD, Zeng K, Xue FQ, Chen JH, Chen YQ (October 2013). "Statins are associated with reduced risk of gastric cancer: a meta-analysis". European Journal of Clinical Pharmacology. 69 (10): 1855–60. doi:10.1007/s00228-013-1547-z. PMID23748751.
^Singh PP, Singh S (July 2013). "Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis". Annals of Oncology. 24 (7): 1721–30. doi:10.1093/annonc/mdt150. PMID23599253.
^Pradelli D, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G (May 2013). "Statins and primary liver cancer: a meta-analysis of observational studies". European Journal of Cancer Prevention. 22 (3): 229–34. doi:10.1097/cej.0b013e328358761a. PMID23010949.
^Zhang Y, Zang T (2013). "Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010". Urologia Internationalis. 90 (3): 259–62. doi:10.1159/000341977. PMID23052323.
^Undela K, Srikanth V, Bansal D (August 2012). "Statin use and risk of breast cancer: a meta-analysis of observational studies". Breast Cancer Research and Treatment. 135 (1): 261–9. doi:10.1007/s10549-012-2154-x. PMID22806241.
^Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, Shi M, Li W, Zheng H, Jiang B (July 2012). "Statin use and risk of pancreatic cancer: a meta-analysis". Cancer Causes & Control. 23 (7): 1099–111. doi:10.1007/s10552-012-9979-9. PMID22562222.
^Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, Wang GC, Xia SQ, Wu Y, Zheng JH (April 2013). "Statin use and risk of bladder cancer: a meta-analysis". Cancer Causes & Control. 24 (4): 769–76. doi:10.1007/s10552-013-0159-3. PMID23361339.
^Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y (Jul–Aug 1991). "Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study". Arteriosclerosis and Thrombosis. 11 (4): 816–26. doi:10.1161/01.ATV.11.4.816. PMID2065035.
^Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J (2007). "Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins". Current Medicinal Chemistry. 14 (2): 243–8. doi:10.2174/092986707779313381. PMID17266583.
^Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM (April 2006). "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". JAMA. 295 (13): 1556–65. doi:10.1001/jama.295.13.jpc60002. PMID16533939.
^Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (November 2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". The New England Journal of Medicine. 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID18997196.
^Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (March 1997). "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved". Drug Metabolism and Disposition. 25 (3): 321–31. PMID9172950.
^Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG (March 2003). "Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals". The American Journal of Cardiology. 91 (5A): 11C–17C, discussion 17C–19C. doi:10.1016/S0002-9149(03)00004-3. PMID12646338.
^Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH (1976). "Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum". Journal of the Chemical Society, Perkin Transactions 1 (11): 1165. doi:10.1039/P19760001165.
^Steinberg D (2007). The cholesterol wars : the skeptics vs. the preponderance of evidence. Academic Press. pp. 6–9. ISBN978-0-12-373979-7.
^Scandinaviansimvastatinsurvival (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–9. doi:10.1016/S0140-6736(94)90566-5. PMID7968073.
^Khurana V, Bejjanki HR, Caldito G, Owens MW (May 2007). "Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans". Chest. 131 (5): 1282–8. doi:10.1378/chest.06-0931. PMID17494779.
^Drapala A, Sikora M, Ufnal M (September 2014). "Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins". Journal of the Renin-Angiotensin-Aldosterone System. 15 (3): 250–8. doi:10.1177/1470320314531058. PMID25037529.